FDA to Accelerate Complex Generic Drug Approvals by Adopting Certara·SLP's MIE Technology
Digital Transformation of Generic Drug Development and the Introduction of MIE
On August 27, 2026, the U.S. Food and Drug Administration (FDA) will host a workshop to discuss strategies for streamlining the development and approval of generic drugs using Model-Integrated Evidence (MIE). The event will focus on how quantitative medicine modeling and simulation can supplement physical clinical data and revolutionize the bioequivalence study process. This represents a paradigm shift in regulatory science, moving away from retrospective data verification towards advanced predictive modeling using mathematical models.
Overcoming High Barriers to Entry in the Complex Generic Market
Complex generics, such as inhalers and long-acting injectable drugs, have historically been difficult to approve due to high technical barriers and complex in vivo drug behavior. However, the introduction of the MIE framework will enable the extensive replacement of actual clinical trials with in silico simulations of in vivo drug disposition through physiologically based pharmacokinetic (PBPK) modeling and population pharmacokinetic (popPK) analysis. This will provide more affordable alternatives to patients more quickly, while also reducing the astronomical clinical costs and failure risks faced by generic manufacturers.
Market Opportunity for Biosimulation Companies
The MIE technology, which is the main topic of discussion at this workshop, centers around advanced biosimulation platforms such as Certara's (CERT) 'Simcyp PBPK Simulator' and Simulations Plus (SLP)'s 'GastroPlus'. Certara's simulator has already been used in over 120 new drug approval processes to replace actual clinical trials, demonstrating its exceptional reliability. As the FDA directly establishes MIE guidelines and expands its industry meeting pilot program, the market dominance of software companies that provide these solutions and contract research organizations (CROs) that utilize them is expected to be further strengthened.
Global Regulatory Standardization and Restructuring of the Generic Market
The FDA's formal adoption of MIE is likely to reshape the global generic market by redefining global pharmaceutical regulatory standards. In 2025, the global complex generic market is estimated at approximately $90.7 billion (USD), and the overall generic market is growing to approximately $411 billion (USD), making the impact of regulatory easing significant. It is certain that major regulatory authorities overseas, such as the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, will benchmark the FDA's proactive establishment of MIE approval guidelines and update their own standards. Therefore, domestic and international generic companies aiming for global expansion must incorporate the model validation criteria to be released at this workshop into their R&D design.
The FDA's establishment of MIE guidelines is a strong signal that will transform the R&D paradigm of the global complex generic market, which is estimated at $90.7 billion in 2025, from a clinical-centric approach to a biosimulation-centric approach. In particular, as the software of Certara (CERT) and Simulations Plus (SLP), which are dominant players in the physiologically based pharmacokinetic (PBPK) simulation market, are adopted as pivotal evidence for demonstrating bioequivalence, the long-term subscription revenue growth of these platform companies will become visible. From the perspective of generic developers, replacing the existing bioequivalence clinical trial phase, which costs tens of millions of dollars and takes several years, with computer simulations will directly provide benefits such as R&D budget savings and shorter approval times. In the medium to long term, it is expected that the lowered regulatory hurdles of global regulatory authorities will accelerate the market entry of complex generics, leading to a ripple effect of increased orders for the professional CRO industry that possesses related software validation technology.